ArticleScientific reports2017
A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- The co-delivery of Programmed Death 1 ligands enhances and prolongs rAAV-mediated gene expression in pre-immunized mice.Gene therapy · 2026Article
- Cell Model for Testing Pharmaceuticals Targeting Human PD-L1.Sovremennye tekhnologii v meditsine · 2024Article
- Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint.Frontiers in immunology · 2023Article
- Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer.Journal for immunotherapy of cancer · 2022Article
- Review
- Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor.Cancer discovery · 2022Article
- EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1.Nature communications · 2022Article
- The role of lipid metabolism in tumor immune microenvironment and potential therapeutic strategies.Frontiers in oncology · 2022Review
- The therapeutic implications of immunosuppressive tumor aerobic glycolysis.Cellular & molecular immunology · 2022Review
- Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1.Nature communications · 2021Article
- Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers.Cancer discovery · 2020Article
- Unripe Black Raspberry (Foods (Basel, Switzerland) · 2020Article
- Anticancer Effect ofFrontiers in immunology · 2020Article
- Article
- Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy.Journal of experimental & clinical cancer research : CR · 2019Review
- TAZ teases T cells with PD-L1.Gland surgery · 2019Article
- Tumor suppression of novel anti-PD-1 antibodies mediated through CD28 costimulatory pathway.The Journal of experimental medicine · 2019Article
- PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model.Nature communications · 2019Article
- Fates of CD8+ T cells in Tumor Microenvironment.Computational and structural biotechnology journal · 2019Review
- Resibufogenin suppresses colorectal cancer growth and metastasis through RIP3-mediated necroptosis.Journal of translational medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huge efforts have been devoted to develop therapeutic monoclonal antibodies targeting human Programmed death-ligand 1 (hPD-L1) for treating various types of human cancers. However, thus far there is no suitable animal model for evaluating the anti-tumor efficacy of such antibodies against hPD-L1. Here we report the generation of a robust and effective system utilizing hPD-L1-expressing mouse tumor cells to study the therapeutic activity and mode of action of anti-human PD-L1 in mice. The model has been validated by using a clinically proven hPD-L1 blocking antibody. The anti-hPD-L1 antibody treatment resulted in potent dose-dependent rejection of the human PD-L1-expressing tumors in mice. Consistent with what have observed in autochthonous mouse tumor models and cancer patients, the hPD-L1 tumor bearing mice treated by anti-hPD-L1 antibody showed rapid activation, proliferation and reinvigoration of the cytolytic effector function of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.